Authorea (Authorea),
Journal Year:
2023,
Volume and Issue:
unknown
Published: Aug. 11, 2023
Background:
Transcutaneous
vagus
nerve
stimulation
(VNS)
showed
early
evidence
of
efficacy
for
the
gait
treatment
Parkinson's
disease.Objectives:
Providing
data
on
neurophysiological
and
clinical
effect
transauricular
VNS
(taVNS).Methods:
Ten
PD
patients
with
recording
deep
brain
(DBS)
have
been
enrolled
in
a
within
participant
design
study,
double-blind
crossover
sham-controlled
trial
taVNS.Subthalamic
local
field
potentials
(beta
band
power),
unified
disease
rating
scales,
digital
timed
up
go
test
(TUG)
were
measured
compared
taVNS-ON
vs.
OFF
during
medication-off/DBS-off
condition.Results:
taVNS
induced
reduction
beta
power
contralateral
subthalamic
nucleus
an
improvement
total
TUG
time,
speed
variability.The
taVNS-induced
correlated
speed.Discussions:
could
help
management
PD.The
present
result
opens
new
trials
chronic
neuromodulation
prospective
cohorts.
Disability and Rehabilitation,
Journal Year:
2024,
Volume and Issue:
46(24), P. 5730 - 5760
Published: Feb. 16, 2024
Transcutaneous
auricular
vagus
nerve
stimulation
(taVNS)
is
an
emerging
non-invasive
neuromodulation
therapy.
This
study
aimed
to
explore
the
therapeutic
use
of
taVNS,
optimal
parameters,
effective
sham
protocols,
and
safety.
Neurotherapeutics,
Journal Year:
2024,
Volume and Issue:
21(3), P. e00354 - e00354
Published: April 1, 2024
Postural
instability
is
a
detrimental
and
often
treatment-refractory
symptom
of
Parkinson's
disease.
While
many
existing
studies
quantify
the
biomechanical
deficits
among
various
postural
domains
(static,
anticipatory,
reactive)
in
this
population,
less
known
regarding
neural
network
dysfunctions
underlying
these
phenomena.
This
review
will
summarize
current
on
cortical
subcortical
activities
during
responses
healthy
subjects
those
with
We
also
effects
therapies,
including
neuromodulation
feedback-based
wearable
devices,
symptoms.
With
recent
advances
implantable
devices
that
allow
chronic,
ambulatory
data
collection
from
patients
disease,
combined
sensors
can
measurements
responses,
future
work
using
enable
better
understanding
mechanisms
control.
Bridging
knowledge
gap
be
critical
first
step
towards
developing
novel
neuromodulatory
interventions
to
enhance
treatment
Frontiers in Neuroscience,
Journal Year:
2024,
Volume and Issue:
18
Published: Aug. 16, 2024
Background
Transcutaneous
Vagal
Nerve
Stimulation
(tVNS)
has
been
used
as
a
promising
noninvasive
neuromodulation
technique
for
the
treatment
of
various
systems.The
aim
this
study
was
to
analyze
research
hotspots
and
future
directions
tVNS
in
21st
century
by
using
bibliometric
methods.
Methods
The
object
literature
related
from
Web
Science
database
2000
May
2024.
In
order
measure
number
issuance,
institutions,
authors,
countries,
keywords,
co-citations,
journals
publication,
we
VOSviewer,
Citespace,
Bibliometrix
R-package,
Scimago
Graphica
software.
A
narrative
review
current
content
conducted
gain
better
understanding
state
field.
Results
total
569
papers
were
included
study.
results
show
that
2024,
publications
shows
an
increasing
trend
year
year,
involving
326
institutions.
United
States,
China,
Germany
are
major
centers.
identified
399
which
roughly
formed
11
natural
clusters,
revealing
mainly
reflected
3
areas:
intervention
efficacy
on
nervous
system
diseases,
mechanism
action
tVNS,
stimulation
mode
tVNS.
top
10
most
cited
references
focus
into
Conclusion
safety
have
confirmed
previous
studies,
but
standardized
protocol
not
yet
developed,
clinical
studies
small
sample
sizes
lack
multicenter
multidisciplinary
collaboration.
Currently,
is
neurological
psychiatric
cardiovascular
some
autoimmune
diseases.
It
expected
field
will
continue
application
central
diseases
exploration
mechanisms,
at
same
time,
with
rise
non-invasive
technology,
other
also
great
potential
development.
Frontiers in Aging Neuroscience,
Journal Year:
2025,
Volume and Issue:
16
Published: Jan. 14, 2025
Transcutaneous
vagus
nerve
stimulation
(tVNS)
has
emerged
as
a
novel
noninvasive
adjunct
therapy
for
advanced
Parkinson's
disease
(PD),
yet
no
quantitative
analysis
had
been
conducted
to
assess
its
therapeutic
effect.
This
review
aimed
investigate
the
efficacy
of
tVNS
on
motor
function,
other
potential
clinical
targets
and
safety
in
various
treatment
conditions.
We
searched
six
databases
randomized
controlled
trials
(RCTs)
that
involved
treating
PD
patients
with
tVNS.
Primary
outcome
was
functions,
including
severity
signs,
functional
mobility
balance,
gait
parameters.
Secondary
outcomes
were
cognition,
emotion,
sleep
related
impairments,
patient
reported
non-motor
outcomes,
any
adverse
events.
All
classified
analyzed
according
duration
medication
condition
an
included
study.
Risk
bias
evaluated
by
referencing
Cochrane
risk
tool
1.0.
Data
Revman
5.4.
6
RCTs
176
included.
Several
functions
measured
during
on-medication
(severity
signs
-0.48
[95%
CI
-0.93,
-0.04],
-0.85,
-0.1],
-0.4
-0.78,
-0.03]),
improved
significantly.
However,
verbal
fluency,
sleep-related
impairment,
fatigue
negatively
impacted
condition.
No
distinct
events
reported.
is
relatively
safe
PD.
It
small
moderate
effects
may
impact
few
outcomes.
Quality
level
evidence
low
further
research
warranted.
https://www.crd.york.ac.uk/prospero/#recordDetails,
identifier
CRD42024503322
(PROSPERO).
npj Parkinson s Disease,
Journal Year:
2025,
Volume and Issue:
11(1)
Published: March 1, 2025
Our
study
aimed
to
investigate
the
neural
mechanisms
of
taVNS
in
motor
symptoms
PD,
focusing
on
topological
properties
cortical
functional
networks
and
excitability.
Thirty-two
PD
patients
underwent
near‐infrared
spectroscopy
transcranial
magnetic
stimulation
evaluation
prior
after
two-week
taVNS,
which
were
controlled
by
20
healthy
controls
(HCs).
exhibited
decreased
nodal
efficiency
(Ne)
right
M1
increased
Ne
left
pre‐motor
supplementary
area
compared
with
HCs.
The
was
negatively
associated
UPDRS-III
scores.
Interestingly,
treatment
improved
increasing
enhancing
intracortical
facilitation
(ICF,
ISI
10,
15
ms).
ICF
(ISI
ms)
correlated
could
improve
information
processing
enhance
disorders.
